Estimates Revisions Perspective Therapeutics, Inc.
Stocks
CATX
US46489V3024
Biotechnology & Medical Research
|
Market Closed -
NYSE
16:00:00 2026-09-28 EDT
|
5-day change | 1st Jan Change | ||
| 2.500 USD | -0.79% |
|
-15.82% | -9.09% |
| 09-20 | Perspective Therapeutics, Inc.(NYSEAM:CATX) dropped from S&P Biotechnology Select Industry Index | CI |
| 09-18 | William Blair Initiates Perspective Therapeutics With Outperform Rating | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- CATX Stock
- Consensus Perspective Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
